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To examine whether treatment with epigallocatechin gallate (EGCG) influences progression of
brain atrophy, reduces clinical and further radiologic disease activity markers, and is safe in
patients with progressive multiple sclerosis (PMS).
Methods
We enrolled 61 patients with primary or secondary PMS in a randomized double-blind, parallel-
group, phase II trial on oral EGCG (up to 1,200 mg daily) or placebo for 36 months with an
optional open-label EGCG treatment extension (OE) of 12-month duration. The primary end
point was the rate of brain atrophy, quantified as brain parenchymal fraction (BPF). The
secondary end points were radiologic and clinical disease parameters and safety assessments.
Results
In our cohort, 30 patients were randomized to EGCG treatment and 31 to placebo. Thirty-eight
patients (19 from each group) completed the study. The primary endpoint was notmet, as in 36
months the rate of decrease in BPF was 0.0092 ± 0.0152 in the treatment group and −0.0078 ±
0.0159 in placebo-treated patients. None of the secondary MRI and clinical end points revealed
group differences. Adverse events of EGCG were mostly mild and occurred with a similar
incidence in the placebo group. One patient in the EGCG group had to stop treatment due to
elevated aminotransferases (>3.5 times above normal limit).
Conclusions
In a phase II trial including patients with multiple sclerosis (MS) with progressive disease
course, we were unable to demonstrate a treatment effect of EGCG on the primary and





This phase II trial provides Class II evidence that for patients with PMS, EGCG was safe, well
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Safe and effective treatment options with neuroprotective
properties for progressive MS (PMS) are an unmet clinical
need.1 In contrast to many approved therapies for the re-
lapsing course,2,3 there are only the monoclonal antibody
ocrelizumab4 for primary progressive MS (PPMS) and the
chemotherapy agent mitoxantrone as well as newly the
sphingosine 1-phosphate receptor modulator siponimod5 for
the treatment of secondary progressive MS (SPMS).
One of the main goals for PMS treatment is to slow pro-
gression of neurologic impairment arising from perma-
nent tissue injury1 often evaluated by the degree of brain
atrophy.6
Epigallocatechin-3-gallate (EGCG) is a polyphenolic green
tea catechin7 with anti-inflammatory and neuroprotective
properties demonstrated in animal and ex vivo studies.8,9 In
experimental autoimmune encephalomyelitis (EAE), an ani-
mal model of MS, it was shown to reduce brain inflammation
and neuronal damage by influencing T-cell proliferation,
inhibiting the activation of nuclear factor-κB (NF-κB), and
exerting antioxidant effects.10–12
Its approval as a dietary supplement with a satisfactory long-
term safety profile13 could make EGCG an attractive treat-
ment for patients with PMS with possible neuroprotective
effects.
The present study investigated the effect of EGCG on brain
atrophy, further radiologic parameters, and clinical disease
activity and safety aspects in patients with PMS during a 36-
month double-blind treatment period. This study was ex-




This monocentric, prospective, phase II, double-blinded,
parallel-group, randomized controlled trial was designed to
evaluate the question whether the oral intake of up to
1,200 mg EGCG reduces the rate of brain atrophy in patients
with PMS and is safe and well tolerated. The study was
conducted in Berlin, Germany, from May 2009 to February
2016. The study is rated Class II because less than 80% of
enrolled patients completed the study.
Patients
Eligibility criteria comprised fulfillment of the 2005 revised
McDonald criteria for MS14 and the diagnosis of PPMS or
SPMS, age between 18 and 65 years, Expanded Disability
Status Scale (EDSS)15 score of 3 to 8 at screening, and a
relapse-free period of at least 30 days before randomization.
No MS disease-modifying therapy was allowed.
Key exclusion criteria were a relapsing-remitting form of MS,
a major systemic or CNS disease, especially such as Parkinson,
Huntington, or Alzheimer disease as well as clinically relevant
predefined laboratory abnormalities (aminotransferases >3.5
times above normal limit), and intake of any potentially
hepatotoxic medication. Additional consumption of green tea
or green tea extract (GTE) was prohibited.
Standard Protocol Approvals, Registrations,
and Participant Consents
The study was approved by the local ethics committees
(LaGeSo ZS EK 10 407/08, new: 08/0407-EK 15) and by the
German Federal Institute for Drugs and Medical Devices
(BfArM). This trial is registered with EudraCT (2008-
005213-22) and clinicaltrials.gov (NCT00799890). It was
conducted according to the Declaration of Helsinki in its
applicable version, and every participant provided written
informed consent before screening.
Data Availability
As far as permitted according to data protection require-
ments and consent provided by the participants, original
data are available from the corresponding author on re-
quest from any qualified investigator within 5 years after
publication.
Randomization and Blinding
To account for potential baseline data imbalances, patients
were stratified before randomization for sex (female and
male) and diagnosis (PPMS and SPMS). Patients were ran-
domly (1:1) assigned to receive either Sunphenon/EGCG
capsules (GTE containing >90% EGCG, product of Taiyo
International, taiyointernational.com) or capsules of placebo
with identical appearance.
Glossary
AAR = annualized atrophy rate; AE = adverse event; ARR = annualized relapse rate; BBB = blood-brain barrier; BDI = Becks
Depression Inventory I; BPF = brain parenchymal fraction; CDP = confirmed disability progression; EAE = experimental
autoimmune encephalomyelitis; EDSS = Expanded Disability Status Scale; EGCG = epigallocatechin gallate; FSS = Fatigue
Severity Scale;GMV = gray matter volume;GTE = green tea extract; ITT = intention to treat;MFIS =Modified Fatigue Impact
Scale;MS = multiple sclerosis;MSFC = MS Functional Composite; OCT = optical coherence tomography; OE = open-label
extension; PAS = primary analysis set; PASAT = Paced Auditory Serial Addition Test; PBVC = Percentage Brain Volume
Change; PMS = progressive MS; PP = per protocol; PPMS = primary progressive MS;RRMS = relapsing-remitting MS; SAE =
serious adverse event; SPMS = secondary progressive MS; TIV = total intracranial volume; WMV = white matter volume.
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A block randomization list was generated by the independent
pharmacy to assign patients either to EGCG or to placebo for
36 months.
Only the pharmacist was aware of treatment allocation
throughout the study; all staff and patients remained blinded
to treatment allocation with the exception of 1 patient who
was prematurely unblinded by having the study medication
analyzed in an external laboratory at his own discretion. This
led to the patient’s exclusion from the study.
Following the blinded randomized part of the study (until month
36), the patients were offered the opportunity to participate in
another 12-month OE, in which all patients received EGCG.
Procedures
Following randomization, patients started treatment with
EGCG or placebo capsules 200 mg daily. Divided into 2
doses, they were escalated after 3 months to 400 mg daily,
after 6 months to 600 mg daily, after 18 months to 800 mg,
and after 30 months to 1,200 mg daily until the end of the
study at month 36.
Patients initially treated with placebo and decided to participate in
the 12-month OE started treatment with EGCG capsules 200 mg
daily, then escalated every 2weekswith 200mg, reaching 1,200mg
after 10 weeks. For the patients treated with EGCG, the dosage
was maintained during OE, until month 48 if they participated.
Patients received containers with EGCG capsules or placebo
sufficient until the next study visit. At each of these visits, drug
accountability was performed (number of taken capsules).
Standardized neurologic assessments including EDSS15 and
MS Functional Composite (MSFC)16,17 consisting of 9-Hole
Peg Test, timed 25-foot walk test, and Paced Auditory Serial
Addition Test (PASAT) were performed by a blinded and
especially trained examiner at the initial screening (which was
at most 1 week before randomization), then every 6 months,
and at every unscheduled visit when a relapse was suspected.
To avoid any training effect in the PASAT, each participant
underwent at least 3 test scorings before study scoring.
At baseline and at month 36, fatigue and depressive symptoms
were assessed by the Fatigue Severity Scale (FSS)18 and
Modified Fatigue Impact Scale (MFIS)19 as well as Becks
Depression Inventory I (BDI).20 An optical coherence to-
mography (OCT) was also performed every 12 months.
Safety assessments included reporting of adverse events
(AEs), medical examinations, and laboratory examinations.
Visits were scheduled every 2–3 months and with short-term
follow-up in case of pathologic results.
MRI Data Acquisition and Analysis
MRI was performed on one 1.5 Tesla scanner (Sonata Sie-
mens, Erlangen, Germany). The MRI protocol included a
T2w fluid-attenuated inversion recovery sequence (TR/TE =
10,000/108 ms, 0.5 × 0.5 × 3 mm3, no gap) and a high-
resolution 3D T1-weighted sequence (magnetization pre-
pared rapid acquisition gradient echo, MPRAGE: TR/TE =
2110/4.38 ms, 1 × 1 × 1 mm3), before and after IV contrast
agent administration. Brain parenchymal fraction (BPF),
percent brain volume change (PBVC), and T2w hyperintense
lesions were quantified at screening and months 12, 24, and
36, whereas contrast-enhancing T1-weighted lesions (CELs)
were quantified at screening and month 36.
Brain atrophy was assessed from lesion infilled MPRAGE im-
ages using 2 approaches. BPF was assessed for each time point
using the CAT12 software package (version 12.5—neuro.uni-
jena.de/cat/). Here, gray matter volume (GMV) and white
matter volume (WMV) and total intracranial volume (TIV)
were segmented and visually checked for segmentation errors.
BPF was calculated as follows: BPF = (GMV + WMV)/TIV.
Atrophy was then calculated as the difference between baseline
and subsequent time points. In an additional approach, the
PBVC was quantified longitudinally using the SIENA pipeline
(FMRIB software package, FSL Version 5.0.9).21
T2w lesion load and CELs were manually segmented using
ITK-SNAP.22 Lesions were infilled in MPRAGE images using
the FSL lesion filling tool (FMRIB software package, FSL
Version 5.0.9).21
Primary and Secondary Outcomes
The primary outcome was the change of BPF23 from baseline
to month 36. Secondary MRI outcome measures were
PBVC21 at month 36, increase (difference from month 36 to
baseline) in number and volume of all T2-weighted (T2w)
hyperintense lesions, and the number and volume of CELs at
month 36. Secondary outcomes of OCT are reported in detail
elsewhere.
Secondary clinical outcome measurements were disability
progression as measured by EDSS and confirmed disability
progression (CDP) defined as a 1-point increase in the EDSS
if the baseline score was 3.0–5.5, or a 0.5-point increase if the
baseline score was 6.0 and above, confirmed at a scheduled
visit 6 months later. Further secondary clinical outcome pa-
rameters were annualized relapse rate (ARR), MSFC, BDI,
FSS, and MFIS.
Safety assessments were also part of the secondary outcomes.
At the end of the OE, the primary and secondary outcome
parameters were assessed again.
Statistical Analysis
The study was initially planned as a double-blind adaptive
pilot study for the inclusion of an initial total of 60 patients
with subsequent sample size recalculation.24 The latter was
not performed due to recruitment difficulties. At the end of
the blinded phase (after 36 months), the study was unblinded,
resulting in 61 patients altogether (30 randomized to verum
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and 31 randomized to placebo) and an OE implemented
(compare CONSORT diagram, figure 1).
Results are expressed as arithmetic mean ± SD, median
(range), or frequencies (%). The primary end point BPF was
assessed using the exact Mann-Whitney test.
Continuous secondary endpoints were tested for differences
between groups by using the nonparametric (exact) Mann-
Whitney test for independent groups. Differences in cate-
gorical variables were tested by the Fisher exact test.
Differences between the verum and placebo group with re-
spect to the whole time course were analyzed using
nonparametric analysis of longitudinal data in a 2-factorial
design25 (first factor (independent): treatment groups, sec-
ond factor (dependent): study visits). This cumulates in 3
tests: differences in groups, significant changes in time, and
interactions between groups and time. When appropriate,
multivariate, nonparametric analysis of covariance26 using
baseline values as covariates was complemented.
Because of the large number of missings and lost to follow-up,
we abstained from a full data set analysis according to the
intention-to-treat (ITT) principle. Instead, we used a modi-
fied ITT approach, in which we excluded patients in both
groups who dropped out of the study (primary analysis set
[PAS], 38 patients). In addition, a per-protocol analysis (PP,
Figure 1 Consort Diagram
ITT = intention-to-treat population; OE = open-label extension; PAS = primary analysis set; PP = per-protocol population.
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37 patients) was performed, omitting patients who severely
violated study protocol (see CONSORT diagram, figure 1).
A p value <0.05was considered statistically significant. All tests of
secondary end points were conducted as exploratory data anal-
ysis. Therefore, no adjustments for multiple testing were made.
Numerical calculations were performed using SAS version 9.4
[TS1M3] copyright 2002-2012 by SAS Institute Inc., Cary,
NC, IBM SPSS Statistics, Version 25, Copyright 1989, 2010
SPSS Inc., an IBM Company, Chicago, IL. and The R Project
for Statistical Computing, Version 3.0.2 (2017-04-21).
Results
Patients
Sixty-one participants were randomly assigned to receive either
EGCG (n = 30) or placebo (n = 31) (figure 1). The EGCG and
placebo group were similar for all baseline variables (table e-1,
links.lww.com/NXI/A420). Thirty-seven percent of patients in
the EGCG group and 39% of those in the placebo group had
primary progressive disease; the others had secondary progressive
disease. All included patients were of Caucasian ethnicity.
Thirty-eight patients (19 from each group) completed the
study and were analyzed for the primary outcome. Twenty-
three patients (11 EGCG [36.7%] and 12 placebo [38.7%])
withdrew from treatment (figure 1), mainly for personal
reasons or change of comedication.
In the EGCG group, 2 patients reported partial intolerability
to the study medication (not specified) and discontinued the
study (dropout), and 1 patient dropped out due to elevated
aminotransferases (>3.5 times above normal limit), which
normalized after seizing medication. Reduction of study drug
dosage was not required in any other patient.
All participants completing the full 36 months had a com-
pliance of at least 80% when evaluating intake of study
medication.
MRI Outcomes
The results of the ITT analyses for the MRI outcome pa-
rameters are summarized in table 1. Regarding the primary
end point difference BPF (BPF [baseline–month 36]), we
observed no difference between groups (EGCG= 0.0092 [SD
0.0152]; placebo = 0.0078 [SD 0.0159]; p = 0.670), giving
annualized atrophy rates (AARs) of 0.31% for verum and
0.26% for the placebo group (difference 0.05%).
Regarding secondary end points at month 36, the EGCG
and the placebo group did not differ in PBVC (p = 0.603,
giving AAR of 0.19% for verum and 0.27% for placebo
Table 1 MRI Outcome Parameters After 36 Months (Primary Analysis Set)
EGCG (n = 19) Placebo (n = 19) p Value
BPF 0.6943 (0.0502) 0.6867 (0.0439) 0.608a
Change from baseline 0.0092 (0.0152) 0.0078 (0.0159) 0.670a
Median 0.7040 (0.6000 to 0.7710) 0.6840 (0.6020 to 0.7560)
Percent brain volume change −0.5659 (0.9818) −0.8013 (1.1996) 0.603a
Median −0.5869 (–2.3057 to 0.9561) −0.9600 (–2.4856 to 0.9701)
No. of T2w lesions 35.21 (16.84) 39.32 (19.28) 0.501a
Change from baseline 1.52 (4.23) 3.78 (4.88) 0.146a
Median 30 (8 to 63) 39 (5 to 76)
Volume of T2w lesions (mL) 17.57 (16.47) 16.90 (17.30) 0.773a
Change from baseline (mL) 1.04 (1.48) 0.52 (2.36) 0.043a
Median 11.65 (1.64 to 64.63) 12.20 (0.91 to 67.98)
No. of CELsb 0.00 (0.00) 0.13 (0.34) 0.964a
Median 0 (0 to 0) 0 (0 to 1)
Volume of CELs (mL)b 0.00 (0.00) 0.00 (0.01) 0.984a
Median 0.00 (0.00 to 0.00) 0 (0.00 to 0.04)
Abbreviations: BPF = brain parenchymal fraction; CEL = contrast-enhancing lesion; EGCG = epigallocatechin-3-gallate.
Data are mean (SD) or median (range).
a Exact Mann-Whitney test.
b Number and volume of CELs for 18 patients of EGCG and 16 patients of the placebo group.
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(difference 0.08%), T2w lesion count and volume, and in
CELs (table 1).
Clinical Outcomes
When evaluating clinical end points (table 2), we found no
difference between groups in EDSS, CDP, the mean change in
EDSS between baseline and at month 36, MSFC and its
subscores, and BDI as well as fatigue scores. Eighteen of 27
patients (66.67%) in the EGCG and 20/28 patients (71.43%)
in the placebo group were relapse free during the study. The
ARR until month 36 and CDP were similar in both groups.
There was no difference between EGCG and placebo in the
ARR between baseline and month 18 and between months 18
and 36 (data not shown).
Table 2 Clinical Outcome Parameters After 36 Months (Primary Analysis Set)
EGCG Placebo p Value
EDSS n = 19 n = 20
Mean 6.08 (1.07) 5.73 (1.12) 0.098a
Change from baseline 0.26 (0.45) 0.57 (0.99) 0.421a
Median 6.5 (3.0–8.0) 6.0 (3.5–8.0)
Annualized relapse rate n = 19 n = 20
Mean 0.24 (0.46) 0.19 (0.44) 0.513a
Progression by EDSS n = 18 n = 19
Number 6 (33.3%) 8 (42.1%) 0.737b
MS functional composite (z-score) n = 12 n = 15
Mean 0.56 (0.45) 0.07 (0.75) 0.931a
Change from baseline 0.16 (0.37) −0.13 (0.38) 0.126a
Paced Auditory Serial Addition test n = 17 n = 20
Mean 51.35 (10.95) 42.05 (14.90) 0.051a
Change from baseline 3.82 (9.65) 1.00 (5.79) 0.292a
9-Hole Peg Test in s (average) n = 16 n = 19
Mean 27.64 (11.36) 31.27 (8.32) 0.117a
Change from baseline 1.48 (7.94) 3.00 (6.82) 0.172a
Timed 25-Foot Walk Test in s (average) n = 14 n = 16
Mean 14.19 (10.61) 10.98 (8.07) 0.275a
Change from baseline 1.99 (9.00) 0.23 (5.85) 0.880a
FSS n = 10 n = 11
Mean 4.41 (2.07) 4.54 (1.76) 0.931a
Change from baseline −0.90 (1.86) −0.38 (1.96) 0.813a
MFIS n = 18 n = 19
Mean 38.89 (21.65) 34.11 (13.59) 0.412a
Change from baseline −3.76 (12.63) 2.06 (12.11) 0.178a
BDI n = 18 n = 18
Mean 9.78 (7.37) 9.00 (6.37) 0.820a
Change from baseline 0.13 (4.98) 0.41 (5.17) 0.610a
Abbreviations: BDI = BeckDepression Inventory; EDSS = ExpandedDisability Status Scale; EGCG= epigallocatechin-3-gallate; FSS = Fatigue Severity Scale;MFIS
= Modified Fatigue Impact Scale.
Data are mean (SD), number (%) or median (range).
a Exact Mann-Whitney test.
b Exact χ2 test.
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The results of the PP analyses concerning primary and all
secondary outcome parameters did not differ from those of
the PAS analyses (data not shown).
Subgroup Analyses
In performed subgroup analyses for patients with lower and higher
BPF (≤median BPF vs >median BPF at baseline) and for patients
with andwithoutCELduring the study, the change inbrain atrophy
was not significantly different between groups. Also in subgroups
with clinically milder disease (EDSS score <5) and in patients with
lower Individual Progression Index (EDSS/years of symptoms),we
could not detect a difference for the primary end point.
Furthermore, no sex effects were found relating to PBVC,
BPF, and EDSS.
Longitudinal Analyses
Longitudinal analyses of the entire time course25 including all
available time points (0, 12, 24, and 36 months) also showed no
difference in MRI and clinical parameters for the primary and
secondary end points. These findings were confirmed by lon-
gitudinal covariance analyses24 (see multivariate longitudinal
analysis for brain atrophy in figure 2 andT2w lesions in figure 3).
Safety
Of the 30 participants in the EGCG group 29 (96.7%) and of
the 31 participants in the placebo group, 28 (90.3%)
experienced 1 or more AEs. Eleven (36.7%) in the EGCG and
10 (32.3%) in the placebo group had a serious adverse event
(SAE). None of the SAEs were considered related to the study
drug. All occurred due to hospitalization of study participants
for various reasons (table e-2, links.lww.com/NXI/A420).
The incidence of SAEs and AEs was similar in both study
groups. The most common AEs (>3%) were flu-like infec-
tions, urinary tract infections, fractures and contusions after
falling, and elevated liver enzymes, without statistical differ-
ence between groups.
Open-Label Extension
Seventeen patients from the EGCGgroup and 15 patients from
the former placebo group were available for follow-up assess-
ments at the end of OE. At month 48, there were no significant
differences in BPF (BPF former EGCG = 0.6911, BPF former
placebo group = 0.6879; p = 0.860). PBVC and clinical pro-
gression parameters (EDSS, MSFC, and subscales) showed no
significant difference between former groups and to the ran-
domized phase of the study (data of the OE not shown).
During OE, AEs and SAEs were similar to the randomized
phase, especially no elevation of liver enzymes or other hep-
atotoxic side effects occurred. However, 2 patients reported
intolerability of study medication and decided to stop
treatment.
Figure 2 Multivariate Longitudinal Analysis of Brain Atrophy Over 48 Months
(A) Primary outcome: brain parenchymal fraction; only a significant effect of time was observed (p < 0.001), no group difference (p = 0.520) and no interaction
(p = 0.647). (B) Secondary outcome: percentage brain volume change; significant effect of time (p < 0.001), no group difference (p = 0 0.476), and no interaction
(p = 0.807). Bars represent 25%–75% quartiles. EGCG = epigallocatechin-3-gallate; OE = open-label extension.
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Discussion
This randomized, placebo-controlled trial failed to show an
effect of oral EGCG on radiographic (brain atrophy, T2w
lesions) and clinical (EDSS, relapses, and MSFC) disease
progression in patients with SPMS or PPMS. These results
challenge preclinical data suggesting a neuroprotective and
anti-inflammatory capacity of EGCG in an animal study with
EAE10 where it was shown that orally applied EGCG de-
creased T-cell proliferation and TNFα production of en-
cephalitogenic T-cells via suppression of NF-κB activation
and inhibited neuronal cell death by interference with reactive
oxygen species formation. These findings provided the ra-
tionale for putative antioxidant and anti-inflammatory effects
of EGCG also in human CNS. However, our results are in line
with a study on EGCG in multiple system atrophy27 and
another study from our group that did not find an effect of oral
EGCG on T2w lesion evolution, PBVC, and clinical disease
measures in patients with relapsing-remitting MS (RRMS).28
A key issue of the negative outcome of our study seems to be
the small sample size of the study. With only 61 patients
included and a dropout rate of more than 30% (mostly due to
personal reasons and less to side effects), our study was un-
derpowered and the effect size was overestimated from the
beginning as we have learned meanwhile.29 A post hoc power
calculation revealed a number of 1936 patients per group
needed to detect the given effect size = 0.092 with a power of
80% and a type 1 error (α) of 5% (2 sided). With the 19
patients per group of our specific cohort, it would only be
possible to detect a high effect size = 1.00.
Even in the recently published MS-SMART Study, in-
vestigating the effects of 3 different neuroprotective sub-
stances with about 100 patients per group, no difference in
PBVC could be detected.30
Our cohort was a representative population of patients with
PMS, including a large proportion of patients who were in a
nonrelapsing stage of PMS and had a high level of established
disability with a median EDSS score of 6.0 at study entry.
Nevertheless, we unexpectedly detected a nonpathologic an-
nual PBVC rate (0.2–0.3% per year) in our study population
in comparison to various other PMS trials examining the ef-
fect of fingolimod,31 siponimod,5 lamotrigine,32 ocrelizumab,4
or natalizumab,33 reporting an annual atrophy rate of
0.4–0.7%, disregarding the verum and placebo group. Only 2
studies with PMS reported a similarly low atrophy rate (ibu-
dilast6 and simvastatin/verum arm34). The possibility to
prove a positive effect of an intervention depends on adequate
Figure 3 Multivariate Longitudinal Analysis of T2w Lesions Over 48 Months
(A) Secondary outcome: median T2w lesion counts; a significant effect of time was observed (p < 0.001), no group difference (p = 0.582) and no interaction (p =
0.417). (B) Secondary outcome: median T2w lesion volume in mL; significant effect of time (p < 0.001), no group difference (p = 0.821), and no interaction (p =
0.324). Bars represent 25%–75% quartiles. EGCG = epigallocatechin gallate; OE = open-label extension.
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dynamics of the investigated variable. Therefore, we may
speculate that our study population was too stable to detect a
beneficial effect on radiographic disease progression markers.
Another possible reason for the negative outcome seems to be
the insufficient bioavailability of oral EGCG in the doses used
in these studies.35 Previous studies had reported doses of up
to 800 mg EGCG per day as safe and generally well tolerated,
e.g., in healthy volunteers, where the plasma elimination half-
life of EGCGwas measured to be about 5 hours after repeated
administration of 800 mg EGCG daily over 10 days.36
Therefore, we chose a maximum daily dose of 800 mg EGCG
until month 30, a maximum daily dose of 1,200 mg until
month 36, and for the optional OE until month 48. Evidence
was found that 600 mg EGCG beneficially influences muscle
metabolism in patients with MS11; however, our dosages were
not sufficient to achieve an effect in the CNS. Recently, a new
study proposed the bioavailability of EGCG to be less than 1%
in humans from ingestion, with a clearance from the systemic
circulation within a few hours.7 Although we did not measure
plasma levels of EGCG in this study, our previous study in
RRMS showed that plasma levels of EGCG are extremely
variable across patients despite equal dosing.28 Moreover,
although passage of EGCG through the blood-brain barrier
(BBB) was shown in animal studies,7 proof of CNS entry of
EGCG in humans is lacking.
In comparison to, e.g., the ocrelizumab ORATORIO trial
(baseline: median EDSS score 4.5), the disease duration and
the EDSS were higher in our study. Furthermore, active
progression just before study entry was not mandatory for our
trial. The nature of the EDSS as an ordinal scale results in
scores that are unequally distributed, and the individuals re-
main at a step in the scale for different lengths of time, es-
pecially at higher EDSS scores despite progressive disability.37
The considerations may explain why in a clinically stable
cohort with high disability levels, subtle positive effects of
EGCG at certain EDSS levels could not be demonstrated.
Although hepatotoxicity has been discussed as a potentially
severe side effect of green tea dietary supplements13 and
Polyphenon,38 we did not observe any related SAE with our
EGCG dosing regimen. In our study, only 1 subject dropped
out due to elevated liver enzymes. Also, in our study on
EGCG in RRMS, no relevant liver toxicity occurred.28 A
possible explanation could be that pure EGCG is less harmful
than GTE or Polyphenon regarding hepatotoxicity. GTE and
Polyphenon contain several types of polyphenols. However,
in the PROMESA study, 8 of 47 patients treated with EGCG
up to a maximum dose of 1,200 mg for up to 40 weeks (48
weeks in total including the dosage phase) experienced hep-
atotoxicity. This was determined as increased aminotrans-
ferase concentrations of which 2 were regarded as SAEs
(aminotransferase concentrations greater than 5 times the
upper limit).27 The concomitant medication with among
others levodopa (which itself may cause elevated liver en-
zymes) and the mean age of the patients being 10 years older
than in the MS studies (possibly leading to more concomitant
diseases) may be an explanation for worse tolerability.
Recent studies reported beneficial effects of orally applied
EGCG on cognitive functions in combination with cognitive
training in patients with Down syndrome and fragile X
syndrome.39,40 Our study also found an improvement of the
PASAT score in both study groups, favoring EGCG (change
from baseline: EGCG 3.82 [SD 9.65], placebo 1.00 [SD
5.79]; p value = 0.051). The PASAT measures cognitive
function such as calculation ability, auditory information
processing speed, and flexibility. These findings may suggest
that EGCG could have a positive effect on the cognitive
functions of patients with PMS. Training effects of the PASAT
due to 3 test scorings before the study are unlikely. However,
this result should be interpreted carefully because it was ob-
served as a statistical trend and our study was not designed to
evaluate this outcome specifically.
EGCG at a dose of up to 1,200 mg daily was overall safe and
well tolerated in patients with PMS over a period of 36
months and a 12-month open-label extension. However, we
did not find an effect of treatment on MRI or clinical disease
activity parameters. Possible explanations include the small
sample size and the high dropout rate. First indications were
found that EGCG treatment may beneficially affect cognitive
functions also in MS. Thus, further investigation in larger MS
cohorts may be warranted, especially for improvement of
cognitive functions with adjuvant treatment. Such studies
should consider using optimized formulations of EGCG for
increased bioavailability and ideally with proven BBB passage.
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